Your session is about to expire
← Back to Search
EDG-5506 for Duchenne Muscular Dystrophy (LYNX Trial)
LYNX Trial Summary
This trial is studying safety, how a drug is absorbed and how it affects biomarkers in kids with Duchenne muscular dystrophy. It will be done in two parts.
LYNX Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LYNX Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can stand up from lying down in less than 10 seconds and climb four stairs in less than 10 seconds.I am 4-7 years old and haven't taken corticosteroids in the last 6 months.My weight is between 15 kg and 35 kg.I have not taken oral steroids for Duchenne muscular dystrophy in the last 6 months.I've been on a stable dose of exon-skipping therapy for less than a year.I am aged 4-9 and have been on a stable dose of corticosteroids for at least 6 months.My lung function is below 60% of what is expected for my age.I have a confirmed genetic mutation for Duchenne muscular dystrophy.
- Group 1: Cohort 3
- Group 2: Cohort 4
- Group 3: Cohort 5
- Group 4: Cohort 2NS
- Group 5: Cohort 2
- Group 6: Cohort 1
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research involve volunteers who are below the age of twenty?
"This trial seeks patients ranging from 4 to 9 years old."
How safe is Cohort 2 for human participants?
"The safety of Cohort 2 scored a 2 on our scale, as there is evidence that it is safe to use but no data yet demonstrating its efficacy."
Are there any open positions available to participants in this investigation?
"The public records on clinicaltrials.gov confirm that this particular medical trial is actively seeking participants, with the first posting having been made on October 1st 2022 and its most recent update occurring in late-October of the same year."
What goals is this trial aiming to accomplish?
"The main aim of the trial, which will be monitored over 12 months, is to assess severity of any adverse events resulting from EDG-5506 and placebo. Additionally, secondary objectives for this experiment include observing changes in neurological examinations among all participants as well as alterations in fast skeletal muscle troponin I levels and coagulation records across all patients."
Which individuals would be ideal candidates for this clinical trial?
"To qualify for this trial, participants must meet the criteria of having muscular dystrophy (Duchenne) and should be between 4 to 9 years old. The study is currently searching for 27 enrollees."
What is the upper limit of participants in this medical research study?
"Indeed, the official data posted on clinicaltrials.gov attests to this experiment's active recruitment process. It was first listed on October 1st 2022 and recently updated on October 24th of the same year. The trial aims to enrol 27 patients from a single site."
Share this study with friends
Copy Link
Messenger